{"id":"NCT00796120","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","briefTitle":"An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)","officialTitle":"A Randomized, Multicenter, Phase III Trial of Trabectedin (Yondelis) Versus Doxorubicin-based Chemotherapy as First-Line Therapy in Patients With Translocation-Related Sarcomas (TRS)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-11","primaryCompletion":"2012-08","completion":"2014-08","firstPosted":"2008-11-24","resultsPosted":"2014-09-16","lastUpdate":"2015-12-10"},"enrollment":121,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Sarcoma"],"interventions":[{"type":"DRUG","name":"Trabectedin","otherNames":[]},{"type":"DRUG","name":"Doxorubicin","otherNames":[]},{"type":"DRUG","name":"Ifosfamide","otherNames":[]}],"arms":[{"label":"Trabectedin","type":"EXPERIMENTAL"},{"label":"Doxorubicin plus Ifosfamide","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of trabectedin compared to standard doxorubicin in participants with advanced translocation-related sarcomas (cancer of connective tissue cells) (TRS).","primaryOutcome":{"measure":"Progression - Free Survival (PFS)","timeFrame":"Every 6 weeks from randomization during the first 9 months and thereafter, every 9 weeks up to 20 months","effectByArm":[{"arm":"Trabectedin","deltaMin":19.6,"sd":null},{"arm":"Doxorubicin Plus Ifosfamide","deltaMin":8.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":21,"countries":["United States","France","Germany","Spain","United Kingdom"]},"refs":{"pmids":["24512981"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":24,"n":61},"commonTop":["Fatigue","Nausea","Tumour pain","Vomiting","Neutropenia"]}}